Benjamin M. Ellingson

Jun 26, 2024 | ajnr.org | Benjamin M. Ellingson

A Neuroradiologist’s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults Benjamin M. Ellingson, Francesco Sanvito, Timothy F. Cloughesy, Raymond Y. Huang, Javier E. Villanueva-Meyer, Whitney B. Pope, Daniel P. Barboriak, Lalitha K. Shankar, Marion Smits, Timothy J. Kaufmann, Jerrold L. Boxerman, Michael Weller, Evanthia Galanis, John de Groot, Mark R. Gilbert, Andrew B. Lassman, Mark S.

May 8, 2024 | nature.com | Richard Everson |Willy Hugo |Lu O. Sun |Joseph K. Antonios |Melissa Bu |Sara Khattab | +9 more

In this randomized phase II clinical trial, we evaluated the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to autologous tumor lysate-pulsed dendritic cell (ATL-DC) vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas. The primary endpoints were to assess the most effective combination of vaccine and adjuvant in order to enhance the immune potency, along with safety. The combination of ATL-DC vaccination and TLR agonist was safe and found to enhance systemic immune responses, as indicated by increased interferon gene expression and changes in immune cell activation. Specifically, PD-1 expression increases on CD4+ T-cells, while CD38 and CD39 expression are reduced on CD8+ T cells, alongside an increase in monocytes. Poly-ICLC treatment amplifies the induction of interferon-induced genes in monocytes and T lymphocytes. Patients that exhibit higher interferon response gene expression demonstrate prolonged survival and delayed disease progression. These findings suggest that combining ATL-DC with poly-ICLC can induce a polarized interferon response in circulating monocytes and CD8+ T cells, which may represent an important blood biomarker for immunotherapy in this patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01204684. Autologous tumor lysate (ATL) dendritic cell (DC) vaccination can induce local and systemic anti-tumor immune responses in malignant glioma patients. In this randomized phase II clinical trial, the authors evaluate the effectiveness of adding the TLR agonists, poly-ICLC or resiquimod, to ATL-DC vaccination in patients with newly-diagnosed or recurrent WHO Grade III-IV malignant gliomas.

Feb 28, 2024 | hal.science | Ingo K. Mellinghoff |Benjamin M. Ellingson |Mehdi Touat |Institut Gustave Roussy

Article Dans Une Revue Journal of Clinical Oncology Année : 2020 Ivosidenib in Isocitrate Dehydrogenase 1 – Mutated Advanced Glioma Fichier principal mellinghoff-et-al-2020-ivosidenib-in-isocitrate-dehydrogenase-1-mutated-advanced-glioma.pdf (1019.09 Ko) Télécharger le fichier Origine : Fichiers éditeurs autorisés sur une archive ouverte Licence : CC BY NC ND - Paternité - Pas d'utilisation commerciale - Pas de modification hal-04481741 , version 1 (28-02-2024) Ingo K Mellinghoff, Benjamin M...